Terms: = Head and neck cancer AND NTRK3, TRKC, 4916, ENSG00000140538, Q16288, gp145 trkC AND Treatment
41 results:
1. Estimating the Prognostic Value of the NTRK Fusion Biomarker for Comparative Effectiveness Research in The Netherlands.
Santi I; Vellekoop H; M Versteegh M; A Huygens S; Dinjens WNM; Mölken MR
Mol Diagn Ther; 2024 May; 28(3):319-328. PubMed ID: 38616205
[TBL] [Abstract] [Full Text] [Related]
2. Macrofollicular Architecture in Invasive Encapsulated Follicular Variant of Papillary Thyroid Carcinoma: A Pitfall in Thyroid Practice.
Yadav S; Kandasamy D; Damle N; Goel R; Chumber S; Sharma MC; Boruah M; Agarwal S
Head Neck Pathol; 2023 Dec; 17(4):899-909. PubMed ID: 37775618
[TBL] [Abstract] [Full Text] [Related]
3. Secretory carcinoma of salivary glands with ntrk3 break-apart molecular rearrangement: Potential misdiagnosis with mucoepidermoid carcinoma.
Nocini R; Sanna G; Trotolo A; Fior A; Brunelli M; Manfrin E; Favero V
J Stomatol Oral Maxillofac Surg; 2023 Dec; 124(6S):101635. PubMed ID: 37709146
[TBL] [Abstract] [Full Text] [Related]
4. Precision oncology using organoids of a secretory carcinoma of the salivary gland treated with TRK-inhibitors.
Lassche G; van Engen-van Grunsven ACH; van Hooij O; Aalders TW; Am Weijers J; Cocco E; Drilon A; Hoischen A; Neveling K; Schalken JA; Verhaegh GW; van Herpen CML
Oral Oncol; 2023 Feb; 137():106297. PubMed ID: 36610231
[TBL] [Abstract] [Full Text] [Related]
5. Clinicopathological significance of major fusion oncogenes in papillary thyroid carcinoma: An individual patient data meta-analysis.
Vuong HG; Le HT; Le TTB; Le T; Hassell L; Kakudo K
Pathol Res Pract; 2022 Dec; 240():154180. PubMed ID: 36306725
[TBL] [Abstract] [Full Text] [Related]
6. TRK Inhibition with Entrectinib in Metastatic Salivary Secretory Carcinoma (SC): A Case Report.
Ernst MS; Lysack JT; Hyrcza MD; Chandarana SP; Hao D
Curr Oncol; 2022 May; 29(6):3933-3939. PubMed ID: 35735423
[TBL] [Abstract] [Full Text] [Related]
7. Systemic therapy for salivary gland malignancy: current status and future perspectives.
Imamura Y; Kiyota N; Tahara M; Hanai N; Asakage T; Matsuura K; Ota I; Saito Y; Sano D; Kodaira T; Motegi A; Yasuda K; Takahashi S; Yokota T; Okano S; Tanaka K; Onoe T; Ariizumi Y; Homma A
Jpn J Clin Oncol; 2022 Apr; 52(4):293-302. PubMed ID: 35134985
[TBL] [Abstract] [Full Text] [Related]
8. Fusion Oncogenes Are Associated With Increased Metastatic Capacity and Persistent Disease in Pediatric Thyroid cancers.
Franco AT; Ricarte-Filho JC; Isaza A; Jones Z; Jain N; Mostoufi-Moab S; Surrey L; Laetsch TW; Li MM; DeHart JC; Reichenberger E; Taylor D; Kazahaya K; Adzick NS; Bauer AJ
J Clin Oncol; 2022 Apr; 40(10):1081-1090. PubMed ID: 35015563
[TBL] [Abstract] [Full Text] [Related]
9. Clinicopathological investigation of secretory carcinoma cases including a successful treatment outcome using entrectinib for high-grade transformation: a case report.
Suzuki K; Harada H; Takeda M; Ohe C; Uemura Y; Kawahara A; Sawada S; Kanda A; Sengupta B; Iwai H
BMC Med Genomics; 2022 Jan; 15(1):6. PubMed ID: 34991563
[TBL] [Abstract] [Full Text] [Related]
10. Secretory Carcinoma in Children and Young Adults: A Case Series.
Simon CT; McHugh JB; Rabah R; Heider A
Pediatr Dev Pathol; 2022; 25(2):155-161. PubMed ID: 34606389
[TBL] [Abstract] [Full Text] [Related]
11. Diverse Oncogenic Fusions and Distinct Gene Expression Patterns Define the Genomic Landscape of Pediatric Papillary Thyroid Carcinoma.
Stosic A; Fuligni F; Anderson ND; Davidson S; de Borja R; Acker M; Forte V; Campisi P; Propst EJ; Wolter NE; Chami R; Mete O; Malkin D; Shlien A; Wasserman JD
Cancer Res; 2021 Nov; 81(22):5625-5637. PubMed ID: 34535459
[TBL] [Abstract] [Full Text] [Related]
12. [Secretory carcinoma of salivary gland: a clinicopathological and prognostic analysis of twelve cases].
Cao YS; Lyu XQ
Zhonghua Bing Li Xue Za Zhi; 2021 Aug; 50(8):899-903. PubMed ID: 34344073
[No Abstract] [Full Text] [Related]
13. Diagnostic challenges and successful organ-preserving therapy in a case of secretory carcinoma of minor salivary glands.
Bill R; Deschler DG; Pittet MJ; Pai SI; Sadow PM; Park JC
Cancer Rep (Hoboken); 2022 Mar; 5(3):e1491. PubMed ID: 34231337
[TBL] [Abstract] [Full Text] [Related]
14. Secretory carcinoma of salivary gland origin: A recently established masquerader.
Budhiraja S; Kumar R; Khanna G; Sagar P; Arava S; Barwad A; Mridha AR
Indian J Cancer; 2021; 58(2):278-284. PubMed ID: 34100414
[TBL] [Abstract] [Full Text] [Related]
15. Targeted DNA profiling and the prevalence of NTRK aberrations in Chinese patients with head and neck cancer.
Xu J; Wang R; Wang T; Wang T; Gu D; He Y; Shu Y; Chen R; Liu L
Oral Oncol; 2021 Aug; 119():105369. PubMed ID: 34098386
[TBL] [Abstract] [Full Text] [Related]
16. Clinical Activity of Selitrectinib in a Patient With Mammary Analogue Secretory Carcinoma of the Parotid Gland With Secondary Resistance to Entrectinib.
Florou V; Nevala-Plagemann C; Whisenant J; Maeda P; Gilcrease GW; Garrido-Laguna I
J Natl Compr Canc Netw; 2021 May; 19(5):478-482. PubMed ID: 34030125
[TBL] [Abstract] [Full Text] [Related]
17. Mammary analog secretory carcinoma of the thyroid gland: A rare cancer harboring TRK fusion.
Huang NS; Cao YM; Lu ZW; Guan Q; Chen JY; Ma B; Chen TZ; Bai QM; Wang YL; Ji QH
Oral Oncol; 2021 Apr; 115():105092. PubMed ID: 33189578
[TBL] [Abstract] [Full Text] [Related]
18. EPR17341 and A7H6R pan-TRK Immunohistochemistry Result in Highly Different Staining Patterns in a Series of Salivary Gland Tumors.
Guibourg B; Cloarec E; Conan-Charlet V; Quintin-Roué I; Grippari JL; Le Flahec G; Marcorelles P; Uguen A
Appl Immunohistochem Mol Morphol; 2020 Oct; 28(9):719-724. PubMed ID: 32187023
[TBL] [Abstract] [Full Text] [Related]
19. Characterization of novel genetic alterations in salivary gland secretory carcinoma.
Na K; Hernandez-Prera JC; Lim JY; Woo HY; Yoon SO
Mod Pathol; 2020 Apr; 33(4):541-550. PubMed ID: 31822803
[TBL] [Abstract] [Full Text] [Related]
20. Rapid, complete and sustained tumour response to the TRK inhibitor larotrectinib in an infant with recurrent, chemotherapy-refractory infantile fibrosarcoma carrying the characteristic ETV6-ntrk3 gene fusion.
Bielack SS; Cox MC; Nathrath M; Apel K; Blattmann C; Holl T; Jenewein R; Klenk U; Klothaki P; Müller-Abt P; Ortega-Lawerenz S; Reynolds M; Scheer M; Simon-Klingenstein K; Stegmaier S; Tupper R; Vokuhl C; von Kalle T
Ann Oncol; 2019 Nov; 30(Suppl_8):viii31-viii35. PubMed ID: 31738425
[TBL] [Abstract] [Full Text] [Related]
[Next]
